Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | EVP Chief Legal Officer | February 13, 2026 | February 18, 2026 |
| INVACARE HOLDINGS CorpIVC · Entity 86444 | Director | April 01, 2022 | April 05, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date February 13, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-02-13 | Direct | 8,450 |
Reported balance
After 2026-02-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-13 · Grant · Acquired 8,450 · Balance 8,450 F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026.
INVACARE HOLDINGS Corp
Report date April 01, 2022 · Filed April 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 104,499 |
Reported balance
After 2022-04-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-04-01 · Grant · Acquired 39,474 · Balance 104,499 F1: Restricted stock units granted pursuant to the Invacare Corporation 2018 Equity Compensation Plan in an exempt transaction under Rule 16b-3. These restricted stock units vest in full on May 15, 2023. F2: Includes 13,388 previously reported restricted stock units issued pursuant to the Invacare Corporation 2018 Equity Compensation Plan, all of which vest in full on May 15, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units granted pursuant to the Invacare Corporation 2018 Equity Compensation Plan in an exempt transaction under Rule 16b-3. These restricted stock units vest in full on May 15, 2023.
F2: Includes 13,388 previously reported restricted stock units issued pursuant to the Invacare Corporation 2018 Equity Compensation Plan, all of which vest in full on May 15, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2017 Filed Mar 2, 2017 22:20 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 593 | $274.76 | $162,932.68 |
DisclosureSEC source: 0001127602-17-009820 · form4.xml · nonDerivative · entry 6 ALEXANDER SUSAN H · CIK 0001263839 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,827 F3 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:20 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,259 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009820 · form4.xml · nonDerivative · entry 5 ALEXANDER SUSAN H · CIK 0001263839 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,420 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:20 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 447 | $287.63 | $128,570.61 |
DisclosureSEC source: 0001127602-17-009820 · form4.xml · nonDerivative · entry 4 ALEXANDER SUSAN H · CIK 0001263839 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,161 F2 · date: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:20 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009820 · form4.xml · nonDerivative · entry 3 ALEXANDER SUSAN H · CIK 0001263839 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,608 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:20 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 335 | $284.75 | $95,391.25 |
DisclosureSEC source: 0001127602-17-009820 · form4.xml · nonDerivative · entry 2 ALEXANDER SUSAN H · CIK 0001263839 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,233 F1 · date: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:20 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 728 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009820 · form4.xml · nonDerivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,568 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 15, 2017 Filed Feb 18, 2017 01:35 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 8,160 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007118 · form4.xml · derivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,160 Underlying: Common Stock · 8,160 shares Expires 2020-02-15 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 16:40 UTC | INVACARE HOLDINGS Corp IVC · Entity 86444 | GrantCommon Shares | 2,839 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-153050 · doc4.xml · nonDerivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,839 F1 · shares: Restricted stock units granted pursuant to the Invacare Corporation 2013 Equity Compensation Plan in an exempt transaction under Rule 16b-3. These restricted stock units vest in full on February 20, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.